Imatinib and chronic-phase leukemias - PubMed (original) (raw)

Comment

Imatinib and chronic-phase leukemias

Laszlo G Boros et al. N Engl J Med. 2002.

No abstract available

PubMed Disclaimer

Comment on

• Imatinib mesylate--a new oral targeted therapy.
  Savage DG, Antman KH. Savage DG, et al. N Engl J Med. 2002 Feb 28;346(9):683-93. doi: 10.1056/NEJMra013339. N Engl J Med. 2002. PMID: 11870247 Review. No abstract available.

Similar articles

• Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
  Goldman JM, Melo JV. Goldman JM, et al. N Engl J Med. 2001 Apr 5;344(14):1084-6. doi: 10.1056/NEJM200104053441409. N Engl J Med. 2001. PMID: 11287980 No abstract available.
• Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML.
  Druker BJ. Druker BJ. Oncogene. 2002 Dec 9;21(56):8541-6. doi: 10.1038/sj.onc.1206081. Oncogene. 2002. PMID: 12476300 Review. No abstract available.
• [Chronic myeloid leukemia and imatinib mesylate therapy].
  Chrobák L. Chrobák L. Vnitr Lek. 2004 Jan;50(1):10-2. Vnitr Lek. 2004. PMID: 15015223 Czech. No abstract available.
• Recent success with the tyrosine kinase inhibitor STI-571--lessons for targeted therapy of cancer.
  Shah NP, Sawyers CL. Shah NP, et al. Curr Opin Investig Drugs. 2001 Mar;2(3):422-3. Curr Opin Investig Drugs. 2001. PMID: 11575716 Review. No abstract available.
• Current treatment approaches for chronic myelogenous leukemia.
  Druker BJ. Druker BJ. Cancer J. 2001 Jul-Aug;7 Suppl 1:S14-8. Cancer J. 2001. PMID: 11504279 Review.

Cited by

• Stable isotope-resolved metabolomics and applications for drug development.
  Fan TW, Lorkiewicz PK, Sellers K, Moseley HN, Higashi RM, Lane AN. Fan TW, et al. Pharmacol Ther. 2012 Mar;133(3):366-91. doi: 10.1016/j.pharmthera.2011.12.007. Epub 2011 Dec 23. Pharmacol Ther. 2012. PMID: 22212615 Free PMC article. Review.
• Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials.
  Schwaederle M, Zhao M, Lee JJ, Eggermont AM, Schilsky RL, Mendelsohn J, Lazar V, Kurzrock R. Schwaederle M, et al. J Clin Oncol. 2015 Nov 10;33(32):3817-25. doi: 10.1200/JCO.2015.61.5997. Epub 2015 Aug 24. J Clin Oncol. 2015. PMID: 26304871 Free PMC article. Review.
• Deuterium Depletion Inhibits Cell Proliferation, RNA and Nuclear Membrane Turnover to Enhance Survival in Pancreatic Cancer.
  Boros LG, Somlyai I, Kovács BZ, Puskás LG, Nagy LI, Dux L, Farkas G, Somlyai G. Boros LG, et al. Cancer Control. 2021 Jan-Dec;28:1073274821999655. doi: 10.1177/1073274821999655. Cancer Control. 2021. PMID: 33760674 Free PMC article.
• Influence of Deuterium-Depleted Water on the Isotope D/H Composition of Liver Tissue and Morphological Development of Rats at Different Periods of Ontogenesis.
  Alexandr Alexandrovich B, Аnna Anatolyevna E, Andrei Alexandrovich S, Nikita Nikolaevich V, Arcadii Victorovich M, Liliya Viacheslavovna F, Mikhail Gennadievich B, Stepan Sergeevich D. Alexandr Alexandrovich B, et al. Iran Biomed J. 2019 Mar;23(2):129-41. doi: 10.29252/.23.2.129. Epub 2018 Sep 17. Iran Biomed J. 2019. PMID: 30220191 Free PMC article.
• A review of applications of metabolomics in cancer.
  Beger RD. Beger RD. Metabolites. 2013 Jul 5;3(3):552-74. doi: 10.3390/metabo3030552. Metabolites. 2013. PMID: 24958139 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Atypon
  • Ovid Technologies, Inc.

• Medical

  • MedlinePlus Health Information